Heres whats covered in this post: The GLP-1 drugs and muscle loss problem what the data actually shows, and why the internet panic is both overblown and underblown in different ways What myostatin is the protein that limits muscle growth, and why scientists have spent 30 years trying to block it Two drugs, two philosophies apitegromab versus bimagrumab, the precision approach versus the heavy hand, and their very different risk profiles The EMBRAZE trial the most exciting recent result, and the critical finding the headlines skipped A brief word on retatrutide the most powerful GLP-1-class drug yet, and a caution worth noting Why a lean, healthy 34-year-old doctor takes low-dose tirzepatide Dr
Ketogenic diets inhibit glycolysis by promoting ketosis and -oxidation
Tirzepatide therapy may not be appropriate for everyone and should never be used without medical supervision
Although 48 studies were identified that evaluated the extent of APAP use in babies and children under 6 years of age, it is difficult to establish exactly how much APAP was used historically and when or where practice changed
BPC-157 and TB-500, for example, are commonly combined this way